To explore the feasibility of RGLD in the treatment of HCC, molecular docking analysis was performed on the core active ingredients of HCC (quercetin, beta-sitosterol, kaempferol, stigmasterol, and isorhamnetin) and the key targets of HCC (VEGFA, HIF1A, CASP8, and TOP2A). This evidence concerns the gene TOP2A and hepatocellular carcinoma.